<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
-------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) April 27, 2000
Bio-Plexus, Inc.
(Exact Name of Registrant as Specified in Charter)
<TABLE>
<S> <C> <C>
Connecticut 0-24128 06-1211921
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
</TABLE>
129 Reservoir Road, Vernon, CT 06066
(Address of Principal Executive Offices)
Registrant's telephone number, including area code (860) 870-6112
(Former Name or Former Address, if Changed Since Last Report)
<PAGE> 2
Item 5. Other Events
Bio-Plexus, Inc. (the "Company") reports that it has named John S. Metz
president and chief executive officer, effective as of April 28, 2000. The press
release related to such appointment is Exhibit 99.1 to this filing, and is
incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIO-PLEXUS, INC.
By: /s/ KIMBERLY A. CADY
--------------------------------
Name: Kimberly A. Cady
Title: Chief Financial Officer and
Vice President of Finance
Date: April 27, 2000
EXHIBIT INDEX
Exhibit No. Description
99.1 Press Release announcing the naming of John S. Metz president
and chief executive officer, effective as of April 28, 2000.
<PAGE> 1
Exhibit 99.1
FOR IMMEDIATE RELEASE
COMPANY CONTACT: Carol Coburn
(860)870-6112, extension 317
[email protected]
BIO-PLEXUS NAMES JOHN S. METZ PRESIDENT AND CEO
VERNON, Conn.--(BW HealthWire)--April 25, 2000--Bio-Plexus today announced that
it has named John S. Metz, 57, president and chief executive officer, effective
April 28, 2000.
Richard Ribakove, Chairman of the Board of Directors commented: "I am pleased to
announce John's appointment as president and chief executive officer. John's
expertise in growing businesses is noted throughout the industry, and his strong
leadership should help Punctur-Guard products penetrate the needle market."
Carl Sahi will remain involved with the company and as a member of the Board of
Directors. "As inventor of Punctur-Guard technology and founder of Bio-Plexus,
Carl has for many years, been the backbone of the company," Ribakove continued.
"He ensured broad patent protection on Punctur-Guard technology and on its
manufacturing process, obtained FDA approval of the technology, brought the
company public, and introduced this innovative technology into the healthcare
workplace. Carl's vision, hard work, and dedication have produced a solidly
grounded company committed to healthcare worker safety. We are much in his
debt," Ribakove concluded.
Metz joins Bio-Plexus from Kimberly-Clark Corporation (NYSE: KMB - news) where
he most recently served as President, Strategic Acquisitions for its
Professional Health Care business. He was also responsible for Kimberly-Clark
Ventures, LLC, -- Kimberly-Clark's venture capital investment arm for emerging
medical technologies and companies. Metz has more than 25 years experience in
the medical product industry, including 8 in marketing for McKesson Corporation
(NYSE: MCK - news) and Becton Dickinson & Company (NYSE: BDX - news).
In 1982, Metz joined Kimberly-Clark as Director of a start-up business unit.
From there, he quickly rose to Vice President of Hospital Sales and Marketing
for Professional Health Care, to Vice President and General Manager, and
ultimately President of Professional Health Care. He is noted for his
achievements in growing businesses through dramatically increased product sales
and through strategic acquisitions. He holds an MBA from Stanford.
<PAGE> 2
"This is a particularly exciting time to be joining Bio-Plexus," Metz commented.
"With OSHA's compliance directive requiring the use of safety needles and 183
members of Congress supporting pending federal safety needle legislation, we are
witnessing a shift in the medical needle market to safety. We have a clear
mandate to deliver Bio-Plexus products into the hands of health care workers,
and I am looking forward to growing Punctur-Guard as the leading name in safety
medical needles," he concluded. Bio-Plexus, Inc. (NASDAQ: BPLX - news), designs,
develops, manufactures and holds U.S. and international patents on safety
medical needles and other products under the PUNCTUR-GUARD(R), DROP-IT(R), and
PUNCTUR-GUARD REVOLUTION(TM) brand names. In studies by the Centers for Disease
Control (January 1997) and ECRI, (Health Devices, June 1998 and October 1999)
Punctur-Guard needles ranked highest of all devices studied. Accidental
needlesticks number about one million per year in the United States and can
result in the transmission of deadly diseases including HIV and Hepatitis B and
C.
NOTE: THIS PRESS RELEASE ISSUED BY THE MANAGEMENT OF BIO-PLEXUS, INC. MAY BE
DEEMED TO CONSTITUTE A SOLICITATION UNDER REGULATION 14A OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. IF ANY STOCKHOLDER OF RECORD AS OF MARCH 24,
2000 HAS NOT ALREADY RECEIVED PROXY MATERIALS CONCERNING THE SPECIAL MEETING OF
STOCKHOLDERS SCHEDULED FOR APRIL 28, 2000, PLEASE NOTE THAT THESE PROXY
MATERIALS WERE FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JANUARY 31,
2000 AND APRIL 3, 2000 AND ARE AVAILABLE FOR FREE AT THE COMMISSION'S WEBSITE:
www.sec.gov, BY ACCESSING BIO-PLEXUS' WEBSITE: WWW.BIO-PLEXUS.COM OR BY
CONTACTING THE COMPANY'S CORPORATE SECRETARY LOCATED AT 129 RESERVOIR ROAD,
VERNON, CONNECTICUT, 06066. THE PROXY MATERIALS CONTAIN IMPORTANT INFORMATION
REGARDING THE PROPOSALS TO BE VOTED UPON AT THE SPECIAL MEETING AND THE COMPANY
URGES STOCKHOLDERS TO READ SUCH INFORMATION CAREFULLY.
- --------------------------------------------------------------------------------
2000
